Navigation Links
Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
Date:5/30/2008

of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
3. Pharmacopeia Announces Management Team Changes
4. Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
7. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
8. Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
11. Verenium Advances Its Development Work With Cargill on a New Food-Related Product

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., ,, BOCA RATON, Fla., Nov. 25 /PRNewswi...l year. Not so for BodyLogicMD. The nation,s larg...ns specializing exclusively in medically supervise... physicians in its network since November 20...s to add more physician-owned centers, including o...
(Date:11/25/2009)... Nov. 25 Ardea Bioscienc...ry D. Quart, Pharm.D., president and chief executi... Annual Health Care Conference. , ,Presentation d...Health Care Conference,Date: Tuesday, Decembe...on: The New York Palace Hotel, New York, NY,Webca...
(Date:11/24/2009)... The New York investment bank KTA Capital,s clie... an AU$6.7 mil convertible note private placement ...acement was arranged by KTA Capital as Neuren,s ex... New York (PRWEB) November 23, 2009 -...ital, LLC ("KTA Capital") has announced ...
(Date:11/24/2009)...S, Nov. 24 Sigma-Aldrich...t the NASDAQ OMX conference on Tuesday, December 1...ested parties may listen via live audio broadcast ...or.sig m a a ldrich.com/ . Users can click t...bout Sigma-Aldrich: Sigma-Aldrich is a leading L...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...g Research Institute Introduce New Research Base a... Diego , , SAN DIEGO, Feb. 11 Leading global bio...nd its affiliate Ferring Research Institute have o...ity located in Sorrento Valley, San Diego that wil...esearch and therapeutics. , , (Photo: http://w...
.... (OTC Bulletin Board: GOVX), an Atlanta-based, pu... human vaccines for diseases caused by HIV-1 (Huma...nts, today announced that Robert McNally, Ph.D., C...corporate update at the Eleventh Annual BIO CEO &a...Astoria Hotel, in New York. , , Dr. McNally prese...
...hronic Pain Indications , , LA JOLLA, Calif., Feb...TX ) today announced that oral administration of N...agonist, was safe and well-tolerated in healthy ma...ive consecutive days. , , "The successful complet... and tolerability of NGX426 when dosed over multip...
Other Biology Technology:Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 2Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 2GeoVax Update Provided at the BIO CEO & Investor Conference 2009 3GeoVax Update Provided at the BIO CEO & Investor Conference 2009 4GeoVax Update Provided at the BIO CEO & Investor Conference 2009 5First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:11/23/2009)..., CINCINNATINew research presents strong evidence...ure to both outdoor traffic-related pollution and ...ngs than one or the other exposure alone. , En... Cincinnati (UC) College of Medicine have shown th...-related particles and indoor endotoxin during ear...
(Date:11/23/2009)..., TORONTO, November 23, 2009 - The time of day ...rding to a new paper produced by a research team l...ronto Scarborough,s vice-principal for research an... biology at the St. George campus. , Capitaliz... the poplar tree, the research team examined how p...
(Date:11/23/2009)..., Farmington, CT Current research suggests that ...disease. The related report by Nichols et al, "Un...t a New Class of TLR2 Ligands Capable of Enhancing... of The American Journal of Pathology . , Multi...tem attacks the brain and spinal cord, affects nea...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Martek to Present at Upcoming Canaccord Adams Conference 52983 1Mathematical modeling predicts response to Herceptin 52980 1Mathematical modeling predicts response to Herceptin 52980 2Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 1Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 2
... CORVALLIS, Ore. Contrary to 40 years of convent...y in the journal Nature suggests that old growth...ue to absorb carbon dioxide from the atmosphere an...r, these old growth forests around the world are n...en considered of no significance in the national "...
... VIRGINIA KEY, Fla. -- The precise timing of the ...ring the past 4.5 billion years has been a subject...rincipal indicator of the amount of organic carbon...d is the ratio of the less abundant isotope of car...lants preferentially incorporate 12C, during perio...
... , Researchers studying a critical stage of pregna...e found a protein that is vital to the growth of n...this protein, which is produced in higher quantiti...kely to survive. , This is the first study to det...rogen spurs cell differentiation and blood-vessel ...
Other Biology News:Old growth forests are valuable carbon sinks 2Old growth forests are valuable carbon sinks 3University of Miami scientist uncovers miscalculation in geological undersea record 2Gap junction protein vital to successful pregnancy, researchers find 2
...ptide sequence corresponding to Tyr89 Gly265 of m...recombinant soluble proform of MT1-MMP purified fr...fic activity of MT1-MMP catalytic domain is = 140 ... mol peptide (7-methoxycoumarin-4-yl)acetyl-Pro-Le...
...current power supply capable of producing up to 50...ce for PAGE, SDS-PAGE and DNA or RNA submarine gel...ng applications.A dual function 100-hour time can ...cally accrue elapsed time when operated in the pas...
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
...100, RVT400, RVT405DDA, RVT4104 and Universal Vacu...DA., A non-corrosive, odorless specially formulat...res ranging from -105 to +260 degrees Celsius. Cry... evaporate. Far superior to dry ice and acetone.,...
Biology Products: